ByTrending Posts
Is AstraZeneca’s Acquisition of Modella AI at JPM…
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at…
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26…
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
Lantern Pharma Secures FDA Orphan Drug Designation for…
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
Can Amgen’s 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Can GSK’s 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its…
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare…
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
Can Roche’s 2025 Launches and Approvals Reinforce Its…
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Trending Posts
Latest Stories
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with…
Obesity Market Poised for $200B+ US Breakthrough by 2040: A Strategic Gold Rush
The US obesity treatment market, valued at $11-15B in 2024, rockets toward $150-200B by 2040…
Gallery
